Deutsch English Français

Contact

EP3817747

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3817747

EP3817747 - TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 25.09.2025 Database last updated on 28.03.2026
Former	Request for examination was made Status updated on 09.04.2021
Former	The international publication has been made Status updated on 11.01.2020
Most recent event Tooltip	21.01.2026	Change: Despatch of examination report + time limit
Applicant(s)	For all designated states Aptamir Therapeutics, Inc. 484 Terracina Way Naples, FL 34119 / US
	[2021/19]
Inventor(s)	01 / THIBONNIER, Marc c/o AptamiR Therapeutics, Inc., 484 Terracina Way Naples, Florida 34119 / US
	[2021/19]
Representative(s)	Cabinet Beau de Loménie 103, rue de Grenelle 75340 Paris Cedex 07 / FR
	[N/P]
Former [2021/19]	Cabinet Beau de Loménie 158, rue de l'Université 75340 Paris Cedex 07 / FR
Application number, filing date	19830492.5	02.07.2019
	[2021/19]
	WO2019US40259
Priority number, date	US201862693025P	02.07.2018 Original published format: US 201862693025 P
	US201962810141P	25.02.2019 Original published format: US 201962810141 P
	[2021/19]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2020010059
	Date:	09.01.2020
	Language:	EN
	[2020/02]
	Type:	A1 Application with search report
	No.:	EP3817747
	Date:	12.05.2021
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.01.2020 takes the place of the publication of the European patent application.
	[2021/19]
Search report(s)	International search report - published on:	US	09.01.2020
	(Supplementary) European search report - dispatched on:	EP	03.06.2022
Classification	IPC:	C12N15/113, A61K9/127, A61K31/7088	[2022/13]
	CPC:	C12N15/111 (EP,KR); A61K9/127 (EP,KR,US); A61K31/05 (EP,US); A61K31/12 (EP); A61K31/20 (EP); A61K31/609 (EP); (+) A61K31/7088 (US); A61K31/7105 (KR); A61K31/713 (EP,KR); A61K47/24 (KR,US); A61K47/28 (KR,US); A61K47/542 (KR); A61K47/543 (US); A61K47/64 (KR,US); A61K47/6911 (KR); A61K47/6913 (KR); A61K9/0019 (EP); A61P29/00 (KR); A61P3/10 (KR); A61P9/00 (KR); C12N15/113 (EP,KR,US); C12N2310/14 (EP,KR); C12N2310/141 (EP,KR,US); C12N2310/3513 (EP,KR,US); C12N2310/3515 (EP,KR,US); C12N2320/32 (EP,KR,US) (-)
	Former IPC [2021/19]	A61K31/498, A61K31/5575, A61K39/395
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/19]
Title	German:	GEZIELTE ABGABE VON THERAPEUTISCHEN MITTELN AN MENSCHLICHE ADIPOZYTEN	[2021/19]
	English:	TARGETED DELIVERY OF THERAPEUTIC AGENTS TO HUMAN ADIPOCYTES	[2021/19]
	French:	ADMINISTRATION CIBLÉE D'AGENTS THÉRAPEUTIQUES À DES ADIPOCYTES HUMAINS	[2021/19]
Entry into regional phase	12.01.2021	National basic fee paid
	12.01.2021	Search fee paid
	12.01.2021	Designation fee(s) paid
	12.01.2021	Examination fee paid
Examination procedure	12.01.2021	Examination requested [2021/19]
	23.11.2022	Amendment by applicant (claims and/or description)
	24.09.2025	Despatch of a communication from the examining division (Time limit: M06)
Fees paid	Renewal fee
	21.06.2021	Renewal fee patent year 03
	02.05.2022	Renewal fee patent year 04
	26.06.2023	Renewal fee patent year 05
	24.06.2024	Renewal fee patent year 06
	24.07.2025	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X] WO2017187426 (APTAMIR THERAPEUTICS INC et al.) [X] 1-10,13-15 * paragraphs [0009] - [0013] - [0082] , [0083] , [0088] , [0093] , [0103] - [0124] - [0143]; examples 15,16; claims 12-32,36,39-55 *
		[A] WO2018031933 (UNIV MASSACHUSETTS et al.) [A] 1-10,13-15 * claims 1,50-61,98-105 *
		[A] WO03084507 (UNIV GIESSEN JUSTUS LIEBIG et al.) [A] 1-10,13-15 * claims 1-6 *
		[A] YOON SHIN PARK ET AL: "In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1 oligonucleotide to adipose tissue reduces adiposity in obese mice", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 161, no. 1, 23 April 2012 (2012-04-23), pages 1 - 9, XP028493062, ISSN: 0168-3659, [retrieved on 20120423], DOI: 10.1016/J.JCONREL.2012.04.026 [A] 1-10,13-15 * page 2, column r; figures 1,2 * DOI: http://dx.doi.org/10.1016/j.jconrel.2012.04.026
		[A] CAO YANG ET AL: "Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment", vol. 7, no. 1, 1 December 2017 (2017-12-01), XP055893444, Retrieved from the Internet DOI: 10.1038/s41598-017-09598-z [A] 1-10,13-15 * figure 1 * DOI: http://dx.doi.org/10.1038/s41598-017-09598-z
		[A] TURNER ET AL: "RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA", BLOOD CELLS, MOLECULES & DISEASES, LAJOLLA, US, vol. 38, no. 1, 23 December 2006 (2006-12-23), pages 1 - 7, XP005733323, ISSN: 1079-9796, DOI: 10.1016/J.BCMD.2006.10.003 [A] 1-10,13-15 * figure 2 * DOI: http://dx.doi.org/10.1016/j.bcmd.2006.10.003
		[A] HOSSEN MD N ET AL: "Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 147, no. 2, 18 July 2010 (2010-07-18), pages 261 - 268, XP027329510, ISSN: 0168-3659, [retrieved on 20100924] [A] 1-10,13-15 * figures 1,2; table 1 *
		[A] YU SAKURAI ET AL: "Advances in an active and passive targeting to tumor and adipose tissues", EXPERT OPINION ON DRUG DELIVERY, vol. 12, no. 1, 7 November 2014 (2014-11-07), GB, pages 41 - 52, XP055754425, ISSN: 1742-5247, DOI: 10.1517/17425247.2015.955847 [A] 1-10,13-15 * table 1 * DOI: http://dx.doi.org/10.1517/17425247.2015.955847
	International search	[X] WO2017187426 (APTAMIR THERAPEUTICS INC et al.) [X] 1-3, 19-21 * ; entire document, especially abstract, claims 12-29, [0006], [0009]-[0011], [0068], [0079], [0248]-[0249] *
		[A] US2009291907 (ESAU CHRISTINE et al.) [A] 1-3, 19-21 * ; entire document *
		[A] US7759318 (PERERA RANJAN et al.) [A] 1-3, 19-21 * ; entire document *
		[A] BOZZUTO ET AL.: "Liposomes as nanomedical devices", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 10, 2 February 2015 (2015-02-02), pages 975 - 999, XP055672583, ISSN: 10.2147/IJN.S68861 [A] 1-3, 19-21 * ; entire document, especially pg 979 col 1 para 5 * DOI: http://dx.doi.org/10.2147/IJN.S68861
	Examination	WO2014036429

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.